| Project/Area Number |
18K16023
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53050:Dermatology-related
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
Nakamura Kenta 信州大学, 医学部, 助教(特定雇用) (90804170)
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | レニンアンジオテンシン / CCL5 / 抗PD-1抗体 / 悪性黒色腫 / 線維芽細胞 / アンジオテンシン |
|---|
| Outline of Final Research Achievements |
Cancer-associated fibroblasts (CAF) that are present in the tumor environment also express angiotensin receptors, and analyses of the effects of CAF on tumor immune responses were performed. Consequently, results showed that, upon stimulation of the renin-angiotensin system, fibroblasts produced CC motif chemokine ligand 5 (CCL5), and CCL5 production was reduced upon administration of an angiotensin receptor inhibitor (ARB). In a mouse model transplanted with malignant melanoma, ARB administration resulted in a decrease in CCL5 in the blood, an increase in tumor-infiltrating T cells, and a decrease in regulatory T cells. Increases in tumor antigen-specific T-cell responses were also observed upon ARB administration. Moreover, an ARB and anti-PD-1 antibody were administered in combination, which resulted in significant tumor growth inhibition over monotherapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
今回の研究結果より、アンジオテンシン受容体阻害薬の投与で、腫瘍免疫応答を増強することができ、抗PD-1抗体との併用効果が示された。抗PD-1抗体は、様々な種類のがんで適応が拡大されており、その治療効果を増強することができれば、多くのがん症例の治療に有益な効果をもたらす可能性がある。また、アンジオテンシン受容体阻害薬は、降圧薬として保険適応があり、併用療法を行うハードルは低いと考えられる。
|
